Thrasos Therapeutics, a Canada-based drug developer focused on acute kidney injuries, has raised $35m from a consortium led by drugs company GlaxoSmithKline’s (GSK) corporate venturing unit. SR One’s commitment came from its GSK Canada Life Sciences Innovation Fund set up at the end of last year. Jens Eckstein, president of SR One, said: “Thrasos’ lead…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
